Amyloid-like inclusions in Huntington's disease
- PMID: 11036200
- DOI: 10.1016/s0306-4522(00)00391-2
Amyloid-like inclusions in Huntington's disease
Abstract
Huntington's disease is a progressive, autosomal dominantly inherited, neurodegenerative disease that is characterized by involuntary movements (chorea), cognitive decline and psychiatric manifestations. This is one of a number of late-onset neurodegenerative disorders caused by expanded glutamine repeats, with a likely similar biochemical basis. Immunohistochemical studies on Huntington's disease tissue, using antibodies raised to the N-terminal region of huntingtin (adjacent to the repeat) and ubiquitin, have recently identified neuronal inclusions within densely stained neuronal nuclei, peri-nuclear and within dystrophic neuritic processes. However, the functional significance of inclusions is unknown. It has been suggested that the disease-causing mechanism in Huntington's disease (and the other polyglutamine disorders) is the ability of polyglutamine to undergo a conformational change that can lead to the formation of very stable anti-parallel beta-sheets; more specifically, amyloid structures. We examined, using Congo Red staining and both polarizing and confocal microscopy, post mortem human brain tissue from five Huntington's disease cases, two Alzheimer's disease cases and two normal controls. Brains from five transgenic mice (R6/2)(12) expressing exon 1 of the human huntingtin gene with expanded polyglutamine, and five littermate controls, were also examined by the same techniques. We have shown that some inclusions in Huntington's disease brain tissue possess an amyloid-like structure, suggesting parallels with other amyloid-associated diseases such as Alzheimer's and prion diseases.
Similar articles
-
Huntingtin protein colocalizes with lesions of neurodegenerative diseases: An investigation in Huntington's, Alzheimer's, and Pick's diseases.Exp Neurol. 1998 Apr;150(2):213-22. doi: 10.1006/exnr.1998.6778. Exp Neurol. 1998. PMID: 9527890
-
Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.J Neurosci Res. 2010 Jan;88(1):179-90. doi: 10.1002/jnr.22184. J Neurosci Res. 2010. PMID: 19642201
-
Insoluble TATA-binding protein accumulation in Huntington's disease cortex.Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):1-10. doi: 10.1016/s0169-328x(02)00450-3. Brain Res Mol Brain Res. 2002. PMID: 12531510
-
Implications of the Orb2 Amyloid Structure in Huntington's Disease.Int J Mol Sci. 2020 Sep 21;21(18):6910. doi: 10.3390/ijms21186910. Int J Mol Sci. 2020. PMID: 32967102 Free PMC article. Review.
-
Bioenergetics in Huntington's disease.Ann N Y Acad Sci. 1999;893:203-13. doi: 10.1111/j.1749-6632.1999.tb07827.x. Ann N Y Acad Sci. 1999. PMID: 10672239 Review.
Cited by
-
A Robust Assay to Monitor Ataxin-3 Amyloid Fibril Assembly.Cells. 2022 Jun 19;11(12):1969. doi: 10.3390/cells11121969. Cells. 2022. PMID: 35741099 Free PMC article.
-
Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?Mol Neurobiol. 2015 Dec;52(3):1297-1314. doi: 10.1007/s12035-014-8932-1. Epub 2014 Oct 22. Mol Neurobiol. 2015. PMID: 25336039 Review.
-
Altered aggregation properties of mutant gamma-crystallins cause inherited cataract.EMBO J. 2002 Nov 15;21(22):6005-14. doi: 10.1093/emboj/cdf609. EMBO J. 2002. PMID: 12426373 Free PMC article.
-
Non-uniform self-assembly: On the anisotropic architecture of α-synuclein supra-fibrillar aggregates.Sci Rep. 2017 Aug 9;7(1):7699. doi: 10.1038/s41598-017-06532-1. Sci Rep. 2017. PMID: 28794461 Free PMC article.
-
Prions, amyloids, and RNA: Pieces of a puzzle.Prion. 2016 May 3;10(3):182-206. doi: 10.1080/19336896.2016.1181253. Prion. 2016. PMID: 27248002 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical